CRVO

CervoMed Inc. · NASDAQ

Sector Commercial Services
Industry Miscellaneous Commercial Services
Website cervomed.com
Employees(FY) 4
ISIN US15713L1098

Performance

+9.27%

-18.11%

-43.66%

-44.61%

+37.48%

YTD

+13.9%

Profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

Advanced Technical Analysis

Technical Analysis of CRVO 2024-12-02

The stock indicators reflect a predominantly neutral sentiment, with the Moving Average Score at 30 indicating bearish momentum, while the Oscillators Score at 50 and Technical Score at 40 suggest a lack of strong directional bias. Overall, the combined scores imply a cautious outlook for the stock, as it struggles to gain bullish momentum.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of CRVO

Stock Rank

Recent News & Updates

2024-11-27 18:17
CervoMeds stock rises as FDA grants orphan drug status to dementia drug(Yahoo Finance)
2024-11-26 18:00
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia(Globenewswire)
2024-11-12 19:00
CervoMed Announces Key Senior Leadership Appointments(Globenewswire)
2024-11-11 18:00
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates(Globenewswire)
2024-11-07 20:55
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup(Globenewswire)
2024-11-06 19:30
CervoMed to Participate in Upcoming Investor Conferences(Globenewswire)
2024-11-03 19:00
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)(Globenewswire)
2024-10-28 20:00
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference(Globenewswire)
2024-10-14 20:00
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)(Globenewswire)
2024-10-04 04:49
CervoMed Ends $20 Million Stock Sales Agreement with BTIG(Yahoo Finance)
2024-10-01 20:00
CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference(Globenewswire)
2024-09-25 20:00
CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)(Globenewswire)
2024-09-19 15:37
CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?(Yahoo Finance)
2024-08-26 20:30
CervoMed to Participate in Upcoming Investor Conferences(Globenewswire)
2024-08-21 20:00
CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies(Globenewswire)
2024-08-11 20:00
CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates(Globenewswire)
2024-08-03 21:03
Morgan Stanley Predicts up to ~230% Surge for These 2 Strong Buy Stocks(Yahoo Finance)
2024-07-29 20:00
CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference(Globenewswire)
2024-07-28 20:00
CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)(Globenewswire)
2024-07-16 20:00
CervoMed to Participate in the Emerging Growth Conference(Globenewswire)
2024-07-16 19:00
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now(Globenewswire)
2024-07-15 19:00
Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now(Globenewswire)
2024-07-10 20:51
CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024(Globenewswire)
2024-07-09 22:52
CRVO Stock Earnings: CervoMed Misses EPS, Beats Revenue for Q4 2023(Investorplace)
2024-06-27 18:50
Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025(Investorplace)
2024-06-23 20:00
CervoMed Announces Addition to Russell 2000 and Russell 3000 Indexes(Globenewswire)
2024-06-10 20:00
CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies(Globenewswire)
2024-05-19 22:09
CervoMed Names William Elder CFO(Yahoo Finance)
2024-05-19 20:00
CervoMed to Appoint William Elder as Chief Financial Officer(Globenewswire)
2024-05-14 21:54
CRVO Stock Earnings: CervoMed Misses EPS, Beats Revenue for Q1 2024(Investorplace)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.